Literature DB >> 17685424

Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.

Ka-Loh Li1, Roland G Henry, Lisa J Wilmes, Jessica Gibbs, Xiaoping Zhu, Ying Lu, Nola M Hylton.   

Abstract

The goal of this study was to investigate the relationship between an empirical contrast kinetic parameter, the signal enhancement ratio (SER), for three-timepoint, high spatial resolution contrast-enhanced (CE) MRI, and a commonly analyzed pharmacokinetic parameter, kep, using dynamic high temporal resolution CE-MRI. Computer simulation was performed to investigate: 1) the relationship between the SER and the contrast agent concentration ratio (CACR) of two postcontrast timepoints (tp1 and tp2); 2) the relationship between the CACR and the redistribution rate constant (kep) based on a two-compartment pharmacokinetic model; and 3) the sensitivity of the relationship between the SER and kep to native tissue T1 relaxation time, T10, and to errors in an assumed vascular input function. The relationship between SER and kep was verified experimentally using a mouse model of breast cancer. The results showed that a monotonic mathematical relationship between SER and kep could be established if the acquisition parameters and the two postinjection timepoints of SER, tp1, tp2, were appropriately chosen. The in vivo study demonstrated a close correlation between SER and kep on a pixel-by-pixel basis (Spearman rank correlation coefficient=0.87+/-0.03). The SER is easy to calculate and may have a unique role in breast tissue characterization. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17685424      PMCID: PMC4508009          DOI: 10.1002/mrm.21361

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  34 in total

1.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?

Authors:  C K Kuhl; P Mielcareck; S Klaschik; C Leutner; E Wardelmann; J Gieseke; H H Schild
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

2.  New criteria for assessing fit quality in dynamic contrast-enhanced T1-weighted MRI for perfusion and permeability imaging.

Authors:  Daniel Balvay; Frédérique Frouin; Guillaume Calmon; Bertrand Bessoud; Edmond Kahn; Nathalie Siauve; Olivier Clément; Charles A Cuenod
Journal:  Magn Reson Med       Date:  2005-10       Impact factor: 4.668

Review 3.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

4.  Pathophysiologic basis of contrast enhancement in breast tumors.

Authors:  M V Knopp; E Weiss; H P Sinn; J Mattern; H Junkermann; J Radeleff; A Magener; G Brix; S Delorme; I Zuna; G van Kaick
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

Review 5.  MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy.

Authors:  M V Knopp; G Brix; H J Junkermann; H P Sinn
Journal:  Magn Reson Imaging Clin N Am       Date:  1994-11       Impact factor: 2.266

Review 6.  A review of 1H nuclear magnetic resonance relaxation in pathology: are T1 and T2 diagnostic?

Authors:  P A Bottomley; C J Hardy; R E Argersinger; G Allen-Moore
Journal:  Med Phys       Date:  1987 Jan-Feb       Impact factor: 4.071

7.  Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours.

Authors:  S Mussurakis; D L Buckley; P J Drew; J N Fox; P J Carleton; L W Turnbull; A Horsman
Journal:  Clin Radiol       Date:  1997-07       Impact factor: 2.350

8.  Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Authors:  Laura Esserman; Nola Hylton; Tracy George; Noel Weidner
Journal:  Breast J       Date:  1999-01       Impact factor: 2.431

9.  Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer.

Authors:  Min-Ying Su; Yun-Chung Cheung; John P Fruehauf; Hon Yu; Orhan Nalcioglu; Eugene Mechetner; Ainura Kyshtoobayeva; Shin-Cheh Chen; Swei Hsueh; Christine E McLaren; Yung-Liang Wan
Journal:  J Magn Reson Imaging       Date:  2003-10       Impact factor: 4.813

10.  MRI estimation of the arterial input function in mice.

Authors:  Stephen Pickup; Rong Zhou; Jerry Glickson
Journal:  Acad Radiol       Date:  2003-09       Impact factor: 3.173

View more
  22 in total

1.  Textural kinetics: a novel dynamic contrast-enhanced (DCE)-MRI feature for breast lesion classification.

Authors:  Shannon C Agner; Salil Soman; Edward Libfeld; Margie McDonald; Kathleen Thomas; Sarah Englander; Mark A Rosen; Deanna Chin; John Nosher; Anant Madabhushi
Journal:  J Digit Imaging       Date:  2011-06       Impact factor: 4.056

2.  Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.

Authors:  Jeon-Hor Chen; Hon Yu; Muqing Lin; Rita S Mehta; Min-Ying Su
Journal:  Magn Reson Imaging       Date:  2013-08-29       Impact factor: 2.546

3.  Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Savannah C Partridge; Risa K Vanantwerp; Robert K Doot; Xiaoyu Chai; Brenda F Kurland; Peter R Eby; Jennifer M Specht; Lisa K Dunnwald; Erin K Schubert; Constance D Lehman; David A Mankoff
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

4.  Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI.

Authors:  Stefan Zwick; Gunnar Brix; Paul S Tofts; Ralph Strecker; Annette Kopp-Schneider; Hendrik Laue; Wolfhard Semmler; Fabian Kiessling
Journal:  Eur Radiol       Date:  2009-09-01       Impact factor: 5.315

5.  Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.

Authors:  Jing Luo; Brian S Johnston; Averi E Kitsch; Daniel S Hippe; Larissa A Korde; Sara Javid; Janie M Lee; Sue Peacock; Constance D Lehman; Savannah C Partridge; Habib Rahbar
Journal:  Radiology       Date:  2017-09-14       Impact factor: 11.105

6.  Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions?

Authors:  Vignesh A Arasu; Ryan C-Y Chen; David N Newitt; C Belinda Chang; Hilda Tso; Nola M Hylton; Bonnie N Joe
Journal:  Acad Radiol       Date:  2011-03-21       Impact factor: 3.173

7.  Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.

Authors:  David C Newitt; Sheye O Aliu; Neil Witcomb; Gal Sela; John Kornak; Laura Esserman; Nola M Hylton
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

8.  Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.

Authors:  Ka-Loh Li; Savannah C Partridge; Bonnie N Joe; Jessica E Gibbs; Ying Lu; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

9.  Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.

Authors:  Peter R Eby; Savannah C Partridge; Steven W White; Robert K Doot; Lisa K Dunnwald; Erin K Schubert; Brenda F Kurland; Constance D Lehman; David A Mankoff
Journal:  Acad Radiol       Date:  2008-10       Impact factor: 3.173

10.  Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.

Authors:  Nazia F Jafri; David C Newitt; John Kornak; Laura J Esserman; Bonnie N Joe; Nola M Hylton
Journal:  J Magn Reson Imaging       Date:  2013-12-18       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.